Cross  ||| S:0 E:6 ||| NNP
sectional  ||| S:6 E:16 ||| JJ
study  ||| S:16 E:22 ||| NN
to  ||| S:22 E:25 ||| TO
investigate  ||| S:25 E:37 ||| VB
the  ||| S:37 E:41 ||| DT
influence  ||| S:41 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
treatment  ||| S:54 E:64 ||| NN
regimes  ||| S:64 E:72 ||| NN
on  ||| S:72 E:75 ||| IN
the  ||| S:75 E:79 ||| DT
development  ||| S:79 E:91 ||| NN
of  ||| S:91 E:94 ||| IN
haemophilic  ||| S:94 E:106 ||| FW
arthropathy  ||| S:106 E:118 ||| FW
Haemophilic  ||| S:118 E:130 ||| FW
arthropathy  ||| S:130 E:142 ||| FW
is  ||| S:142 E:145 ||| VBZ
often  ||| S:145 E:151 ||| RB
present  ||| S:151 E:159 ||| VB
in  ||| S:159 E:162 ||| IN
patients  ||| S:162 E:171 ||| NNS
with  ||| S:171 E:176 ||| IN
severe  ||| S:176 E:183 ||| JJ
haemophilia ||| S:183 E:194 ||| NN
.  ||| S:194 E:196 ||| .
New  ||| S:196 E:200 ||| JJ
studies  ||| S:200 E:208 ||| NNS
demonstrate  ||| S:208 E:220 ||| VBP
that  ||| S:220 E:225 ||| IN
only  ||| S:225 E:230 ||| RB
a  ||| S:230 E:232 ||| DT
small  ||| S:232 E:238 ||| JJ
amount  ||| S:238 E:245 ||| NN
and  ||| S:245 E:249 ||| CC
a  ||| S:249 E:251 ||| DT
short  ||| S:251 E:257 ||| JJ
exposure  ||| S:257 E:266 ||| NN
of  ||| S:266 E:269 ||| IN
blood  ||| S:269 E:275 ||| NN
in  ||| S:275 E:278 ||| IN
vitro  ||| S:278 E:284 ||| NNS
are  ||| S:284 E:288 ||| VBP
able  ||| S:288 E:293 ||| JJ
to  ||| S:293 E:296 ||| TO
induce  ||| S:296 E:303 ||| VB
an  ||| S:303 E:306 ||| DT
impairment  ||| S:306 E:317 ||| NN
of  ||| S:317 E:320 ||| IN
the  ||| S:320 E:324 ||| DT
joint  ||| S:324 E:330 ||| JJ
cartilage ||| S:330 E:339 ||| NN
.  ||| S:339 E:341 ||| .
Free  ||| S:341 E:346 ||| JJ
blood  ||| S:346 E:352 ||| NN
in  ||| S:352 E:355 ||| IN
the  ||| S:355 E:359 ||| DT
joint  ||| S:359 E:365 ||| JJ
leads  ||| S:365 E:371 ||| NNS
to  ||| S:371 E:374 ||| TO
different  ||| S:374 E:384 ||| JJ
mechanisms  ||| S:384 E:395 ||| NNS
and  ||| S:395 E:399 ||| CC
includes  ||| S:399 E:408 ||| VBZ
cartilage  ||| S:408 E:418 ||| NN
and  ||| S:418 E:422 ||| CC
bone  ||| S:422 E:427 ||| NN
damage  ||| S:427 E:434 ||| NN
induced  ||| S:434 E:442 ||| NN
by  ||| S:442 E:445 ||| IN
a  ||| S:445 E:447 ||| DT
release  ||| S:447 E:455 ||| NN
of  ||| S:455 E:458 ||| IN
macrophages  ||| S:458 E:470 ||| NN
and  ||| S:470 E:474 ||| CC
monocytes  ||| S:474 E:484 ||| VB
followed  ||| S:484 E:493 ||| VBN
by  ||| S:493 E:496 ||| IN
activated  ||| S:496 E:506 ||| JJ
cytokines  ||| S:506 E:516 ||| NN
and  ||| S:516 E:520 ||| CC
inflammatory  ||| S:520 E:533 ||| JJ
processes ||| S:533 E:542 ||| NNS
.  ||| S:542 E:544 ||| .
Another  ||| S:544 E:552 ||| DT
mechanism  ||| S:552 E:562 ||| NN
is  ||| S:562 E:565 ||| VBZ
mediated  ||| S:565 E:574 ||| VBN
by  ||| S:574 E:577 ||| IN
free  ||| S:577 E:582 ||| JJ
iron  ||| S:582 E:587 ||| NN
resulting  ||| S:587 E:597 ||| VBG
in  ||| S:597 E:600 ||| IN
synovitis  ||| S:600 E:610 ||| NN
and  ||| S:610 E:614 ||| CC
synovial  ||| S:614 E:623 ||| JJ
hyperplasia  ||| S:623 E:635 ||| NN
and  ||| S:635 E:639 ||| CC
a  ||| S:639 E:641 ||| DT
neoangiogenesis  ||| S:641 E:657 ||| NN
on  ||| S:657 E:660 ||| IN
the  ||| S:660 E:664 ||| DT
base  ||| S:664 E:669 ||| NN
of  ||| S:669 E:672 ||| IN
VEGF  ||| S:672 E:677 ||| NNP
release  ||| S:677 E:685 ||| NN
is  ||| S:685 E:688 ||| VBZ
common ||| S:688 E:694 ||| JJ
.  ||| S:694 E:696 ||| .
At  ||| S:696 E:699 ||| IN
worst ||| S:699 E:704 ||| JJS
,  ||| S:704 E:706 ||| ,
these  ||| S:706 E:712 ||| DT
processes  ||| S:712 E:722 ||| JJ
result  ||| S:722 E:729 ||| NN
in  ||| S:729 E:732 ||| IN
a  ||| S:732 E:734 ||| DT
complete  ||| S:734 E:743 ||| JJ
picture  ||| S:743 E:751 ||| NN
of  ||| S:751 E:754 ||| IN
haemophilic  ||| S:754 E:766 ||| JJ
arthropathy  ||| S:766 E:778 ||| NNS
reducing  ||| S:778 E:787 ||| VBG
quality  ||| S:787 E:795 ||| NN
of  ||| S:795 E:798 ||| IN
life ||| S:798 E:802 ||| NN
.  ||| S:802 E:804 ||| .
Few  ||| S:804 E:808 ||| JJ
studies  ||| S:808 E:816 ||| NNS
are  ||| S:816 E:820 ||| VBP
available  ||| S:820 E:830 ||| JJ
about  ||| S:830 E:836 ||| IN
the  ||| S:836 E:840 ||| DT
influence  ||| S:840 E:850 ||| NN
of  ||| S:850 E:853 ||| IN
factor  ||| S:853 E:860 ||| NN
treatment  ||| S:860 E:870 ||| NN
regime ||| S:870 E:876 ||| NN
,  ||| S:876 E:878 ||| ,
e.  ||| S:878 E:881 ||| CD
g.  ||| S:881 E:884 ||| CD
prophylaxis  ||| S:884 E:896 ||| NNS
or  ||| S:896 E:899 ||| CC
on-demand  ||| S:899 E:909 ||| JJ
therapy ||| S:909 E:916 ||| NN
,  ||| S:916 E:918 ||| ,
on  ||| S:918 E:921 ||| IN
the  ||| S:921 E:925 ||| DT
development  ||| S:925 E:937 ||| NN
of  ||| S:937 E:940 ||| IN
haemophilic  ||| S:940 E:952 ||| JJ
arthropathy ||| S:952 E:963 ||| NN
.  ||| S:963 E:965 ||| .
However  ||| S:965 E:973 ||| RB
these  ||| S:973 E:979 ||| DT
studies  ||| S:979 E:987 ||| NNS
investigated  ||| S:987 E:1000 ||| VBN
in  ||| S:1000 E:1003 ||| IN
most  ||| S:1003 E:1008 ||| JJS
cases  ||| S:1008 E:1014 ||| NNS
children ||| S:1014 E:1022 ||| NNS
.  ||| S:1022 E:1024 ||| .
Therefore ||| S:1024 E:1033 ||| RB
,  ||| S:1033 E:1035 ||| ,
it  ||| S:1035 E:1038 ||| PRP
is  ||| S:1038 E:1041 ||| VBZ
still  ||| S:1041 E:1047 ||| RB
impossible  ||| S:1047 E:1058 ||| JJ
to  ||| S:1058 E:1061 ||| TO
give  ||| S:1061 E:1066 ||| VB
recommendations  ||| S:1066 E:1082 ||| NNS
for  ||| S:1082 E:1086 ||| IN
the  ||| S:1086 E:1090 ||| DT
right  ||| S:1090 E:1096 ||| JJ
treatment  ||| S:1096 E:1106 ||| NN
in  ||| S:1106 E:1109 ||| IN
adult  ||| S:1109 E:1115 ||| NN
haemophilic  ||| S:1115 E:1127 ||| NN
patients  ||| S:1127 E:1136 ||| NNS
because  ||| S:1136 E:1144 ||| IN
data  ||| S:1144 E:1149 ||| NNS
are  ||| S:1149 E:1153 ||| VBP
still  ||| S:1153 E:1159 ||| RB
lacking ||| S:1159 E:1166 ||| VBG
.  ||| S:1166 E:1168 ||| .
For  ||| S:1168 E:1172 ||| IN
that  ||| S:1172 E:1177 ||| DT
reason ||| S:1177 E:1183 ||| NN
,  ||| S:1183 E:1185 ||| ,
we  ||| S:1185 E:1188 ||| PRP
attempt  ||| S:1188 E:1196 ||| VBP
to  ||| S:1196 E:1199 ||| TO
initiate  ||| S:1199 E:1208 ||| VB
the  ||| S:1208 E:1212 ||| DT
HemArthro-Project  ||| S:1212 E:1230 ||| JJ
to  ||| S:1230 E:1233 ||| TO
investigate  ||| S:1233 E:1245 ||| VB
the  ||| S:1245 E:1249 ||| DT
influence  ||| S:1249 E:1259 ||| NN
of  ||| S:1259 E:1262 ||| IN
treatment  ||| S:1262 E:1272 ||| NN
therapy  ||| S:1272 E:1280 ||| NN
on  ||| S:1280 E:1283 ||| IN
the  ||| S:1283 E:1287 ||| DT
development  ||| S:1287 E:1299 ||| NN
of  ||| S:1299 E:1302 ||| IN
arthropathy  ||| S:1302 E:1314 ||| NN
in  ||| S:1314 E:1317 ||| IN
adult  ||| S:1317 E:1323 ||| NN
haemophilic  ||| S:1323 E:1335 ||| NN
patients ||| S:1335 E:1343 ||| NNS
.  ||| S:1343 E:1345 ||| .
This  ||| S:1345 E:1350 ||| DT
study  ||| S:1350 E:1356 ||| NN
includes  ||| S:1356 E:1365 ||| VBZ
the  ||| S:1365 E:1369 ||| DT
investigation  ||| S:1369 E:1383 ||| NN
of  ||| S:1383 E:1386 ||| IN
functional  ||| S:1386 E:1397 ||| JJ
musculoskeletal  ||| S:1397 E:1413 ||| JJ
parameters  ||| S:1413 E:1424 ||| NNS
for  ||| S:1424 E:1428 ||| IN
the  ||| S:1428 E:1432 ||| DT
description  ||| S:1432 E:1444 ||| NN
of  ||| S:1444 E:1447 ||| IN
joint  ||| S:1447 E:1453 ||| JJ
function  ||| S:1453 E:1462 ||| NN
in  ||| S:1462 E:1465 ||| IN
maximal  ||| S:1465 E:1473 ||| CD
500  ||| S:1473 E:1477 ||| CD
severe  ||| S:1477 E:1484 ||| JJ
haemophilic  ||| S:1484 E:1496 ||| JJ
patients  ||| S:1496 E:1505 ||| NNS
parted  ||| S:1505 E:1512 ||| VBD
into  ||| S:1512 E:1517 ||| IN
two  ||| S:1517 E:1521 ||| CD
groups  ||| S:1521 E:1528 ||| NNS
of  ||| S:1528 E:1531 ||| IN
treatment  ||| S:1531 E:1541 ||| NN
regime  ||| S:1541 E:1548 ||| NN
( ||| S:1548 E:1549 ||| -LRB-
prophylaxis  ||| S:1549 E:1561 ||| FW
vs.  ||| S:1561 E:1565 ||| FW
on-demand ||| S:1565 E:1574 ||| FW
) ||| S:1574 E:1575 ||| -RRB-
.  ||| S:1575 E:1577 ||| .
The  ||| S:1577 E:1581 ||| DT
investigators  ||| S:1581 E:1595 ||| NNS
are  ||| S:1595 E:1599 ||| VBP
seeking  ||| S:1599 E:1607 ||| VBG
further  ||| S:1607 E:1615 ||| JJ
assistance  ||| S:1615 E:1626 ||| NN
from  ||| S:1626 E:1631 ||| IN
the  ||| S:1631 E:1635 ||| DT
haemophilic  ||| S:1635 E:1647 ||| JJ
treatment  ||| S:1647 E:1657 ||| NN
centers  ||| S:1657 E:1665 ||| NNS
for  ||| S:1665 E:1669 ||| IN
the  ||| S:1669 E:1673 ||| DT
support  ||| S:1673 E:1681 ||| NN
of  ||| S:1681 E:1684 ||| IN
this  ||| S:1684 E:1689 ||| DT
study ||| S:1689 E:1694 ||| NN
.  ||| S:1694 E:1696 ||| .
